ArticleOncogene2008
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.
Article in Oncogene, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 65 citations in OpenAlex.
- Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.Familial cancer · 2012Trial
- Overexpression of Estrogen Receptor α in Mammary Glands of Aging Mice Is Associated with a Proliferative Risk Signature and Generation of Estrogen Receptor α-Positive Mammary Adenocarcinomas.The American journal of pathology · 2023Article
- Bilateral Salpingo-oophorectomy and Breast Cancer Risk forCancer prevention research (Philadelphia, Pa.) · 2021Review
- Disruption of STAT5A and NMI signaling axis leads to ISG20-driven metastatic mammary tumors.Oncogenesis · 2021Article
- Non-Genomic Actions of Estrogens on the DNA Repair Pathways Are Associated With Chemotherapy Resistance in Breast Cancer.Frontiers in oncology · 2021Review
- Environmental Exposures during Puberty: Window of Breast Cancer Risk and Epigenetic Damage.International journal of environmental research and public health · 2020Review
- Environmental exposures during windows of susceptibility for breast cancer: a framework for prevention research.Breast cancer research : BCR · 2019Review
- Peroxisome proliferator-activated receptor gamma and BRCA1.Endocrine-related cancer · 2019Review
- BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.Breast cancer research and treatment · 2017Article
- Responsiveness ofCancer prevention research (Philadelphia, Pa.) · 2017Article
- Article
- Primary cancer cell culture: mammary-optimized vs conditional reprogramming.Endocrine-related cancer · 2016Article
- MicroRNA-206 is differentially expressed in Brca1-deficient mice and regulates epithelial and stromal cell compartments of the mouse mammary gland.Oncogenesis · 2016Article
- A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance.Oncotarget · 2015Article
- Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.Carcinogenesis · 2015Article
- Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.Molecular endocrinology (Baltimore, Md.) · 2014Article
- Genetically engineered ERα-positive breast cancer mouse models.Endocrine-related cancer · 2014Review
- Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.Cancer biology & therapy · 2014Article
- Estrogen signaling and the DNA damage response in hormone dependent breast cancers.Frontiers in oncology · 2014Review
- BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?International journal of biological sciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
BRCA1 can regulate estrogen receptor-alpha (ERalpha) activity. This study tested the hypotheses that Brca1 loss in mammary epithelium alters the estrogenic growth response and that exposure to increased estrogen or ERalpha collaborates with Brca1 deficiency to accelerate preneoplasia and cancer development. Longer ductal extension was found in mammary glands of Brca1(f/f;MMTV-Cre) mice during puberty as compared to wild-type mice. Terminal end bud differentiation was impaired in Brca1 mutant mice with preservation of prolactin-induced alveolar differentiation. Exogenous estrogen stimulated an abnormal sustained increase in mammary epithelial cell proliferation and the appearance of ERalpha-negative preneoplasia in postpubertal Brca1 mutant mice. Carcinogenesis was investigated using Brca1(f/f;MMTV-Cre) mice hemizygous for p53. Exogenous estrogen increased the percentage of mice with multiple hyperplastic alveolar nodules. Targeted conditional ERalpha overexpression in mammary epithelial cells of mice that were Brca1 mutant and hemizygous for p53 increased the percentage of mice exhibiting multiple hyperplastic nodules, invasive mammary cancers and cancer multiplicity. Significantly more than half of the preneoplasia and cancers were ERalpha negative even as their initiation was promoted by ERalpha overexpression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.